iPS Cell Manufacture and Banking

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
Whole Blood DonationN/A
CD
Cellular DynamicsWI - Madison
1 program
Whole Blood DonationN/A1 trial
Active Trials
NCT03434808TerminatedEst. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Cellular DynamicsWhole Blood Donation

Clinical Trials (1)

NCT03434808Cellular DynamicsWhole Blood Donation

Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population

Start: Jan 2017Est. completion: Aug 2018
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space